Physician profile
Jack Goldman
NPI 1023065539
$31,685.31
in general payments reported to CMS, 2019-2025
46 companies · $3,887 in 2025
The $3,887 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,550 · 2020: $1,748 · 2021: $3,442 · 2022: $10K · 2023: $3,398 · 2024: $2,370 · 2025: $3,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,148 · Consulting Fee: $500 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,147.67 |
| Consulting Fee | $500.00 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $10,440.06 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Novo Nordisk INC | $2,421.88 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $2,337.68 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $2,315.22 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $2,286.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,960.20 | 2021-2025 | |
| Lilly USA, LLC | $1,624.84 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $977.99 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $891.51 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $613.59 | 2021-2025 | |
| Allergan, INC. | $548.11 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.24 | 2023-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $430.96 | 2019-2023 | |
| Amarin Pharma, INC. | $418.67 | 2019-2020 | |
| Pfizer INC. | $414.39 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.